Independent Medical and Patient Education/Advocacy Grants
Vertex Pharmaceuticals funds independent medical education and patient advocacy projects to advance research and care in cystic fibrosis, sickle cell disease, type 1 diabetes, and related diseases.
Browse similar grants
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | February 27, 2026 (Beta Thalassemia & Sickle Cell Disease ISS RFP)
Funding Amounts: No set cap; requests should reflect fair market value and not exceed 30% of an organization's annual budget per year.
Summary: Supports independent medical and patient education/advocacy initiatives in cystic fibrosis, sickle cell disease, type 1 diabetes, and related areas.
Key Information: Applications accepted year-round for most programs; specific RFP windows for some disease areas.
Description
Vertex Pharmaceuticals offers grants to support independent medical education (IME), patient education, and advocacy initiatives that align with their research priorities. The program is designed to advance knowledge and improve care for individuals living with cystic fibrosis, sickle cell disease, type 1 diabetes, beta thalassemia, APOL1-mediated kidney disease, IgA nephropathy, rare diseases, and, in the U.S., acute pain. Both accredited and non-accredited educational activities, as well as patient advocacy projects, are eligible. Funding is available globally in countries where Vertex operates.
